Document is current

Article History

Accepted: 14 November 2021

First Online: 26 November 2021

Declarations

:

: Mentioned in materials and methods.

: Not applicable

: Not applicable

: The authors declare no competing interests.

: What are already known in this context?• The most definitive treatment for TAA is an open aortic repair with a mortality rate of up to 10% within 1 month after the operation.• Today there is a lack of knowledge about TAA pathology, so specific drugs for the TAA have not been proposed yet.• Using satralizumab as an IL-6 receptor blocker was proven safe and effective in neuromyelitis.What is the main question?• Is satralizumab able to prevent the beginning and progression of thoracic aorta aneurysm?What are the new findings?• Antagonizing the IL-6 receptor by satralizumab attenuated the formation of the dTAA and decreased the growth rate of dTAA.What are the impacts on clinical practice?• Satralizumab can be considered a potential anti-aneurysm agent in predisposed patients to prevent the emerging and development of the descending thoracic aorta aneurysm.